Table 8:

Changes in Interventional Treatments, by AUA Risk Group, in a Study of Impact of Prolaris Cycle Cell Progression Test on Treatment Selection

Treatment	Δ Low Risk, % (n = 486)	Δ Intermediate Risk, % (n = 506)	Δ High Risk, % (n = 214)
Radical prostatectomy	−32.4	−37.4	−27.7
EBRT primary	−48.8	−35.0	−37.6
EBRT adjuvant	−60.0	−63.3	−44.0
CyberKnife robotic surgery	−50.0	−60.0	−66.7
Proton beam radiation	−83.3	−71.4	−100
Brachytherapy interstitial	−46.0	−43.1	−55.2
Brachytherapy high dose rate	−69.2	−63.3	−53.8
ADT primary	NAa	−33.3	+10.5
ADT neoadjuvant	+25.0	+32.5	−32.4
ADT adjuvant	0.0	−19.2	+27.3
ADT concurrent	NAb	−42.3	−57.1
Pelvic lymph node dissection	−50.0	−29.4	−50.0
Cryosurgery	−56.5	−64.6	−73.9
High-intensity focused ultrasound	−93.3	−100.0	−100.0
Otherc	+200.0	−25.0	−25.0

Abbreviations: ADT, androgen-deprivation therapy; AUA, American Urological Association; EBRT, external beam radiation therapy.

^aAn increase from zero low-risk patients to 2 was observed.

^bNo low-risk patients were recommended or administered this treatment.

^cOther recommended treatments that did not fall into another category (no details reported).

Source: Shore et al, 2016.⁵⁶